Stockreport

The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease

Horizon Therapeutics Public Limited Company - Ordinary Shares  (HZNP) 
Last horizon therapeutics public limited company - ordinary shares earnings: 2/26 07:00 am Check Earnings Report
PDF -- Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease -- DUBLIN--(BUSINESS WIRE)--Horizon T [Read more]